Jane Street’s Oramed Pharmaceuticals ORMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $545K | Buy |
113,349
+60,809
| +116% | +$242K | ﹤0.01% | 7809 |
|
|
2026
Q1 | $179K | Sell |
52,540
-25,719
| -33% | -$87.3K | ﹤0.01% | 10256 |
|
|
2025
Q4 | $223K | Buy |
78,259
+18,600
| +31% | +$48K | ﹤0.01% | 9504 |
|
|
2025
Q3 | $158K | Buy |
59,659
+17,292
| +41% | +$38.2K | ﹤0.01% | 9851 |
|
|
2025
Q2 | $95.3K | Sell |
42,367
-24,806
| -37% | -$54.7K | ﹤0.01% | 8970 |
|
|
2025
Q1 | $144K | Buy |
67,173
+17,510
| +35% | +$40.4K | ﹤0.01% | 8637 |
|
|
2024
Q4 | $120K | Sell |
49,663
-8,637
| -15% | -$20.5K | ﹤0.01% | 8682 |
|
|
2024
Q3 | $142K | Buy |
58,300
+2,230
| +4% | +$5.44K | ﹤0.01% | 8842 |
|
|
2024
Q2 | $144K | Sell |
56,070
-30,354
| -35% | -$72.1K | ﹤0.01% | 8597 |
|
|
2024
Q1 | $252K | Sell |
86,424
-9,094
| -10% | -$25.4K | ﹤0.01% | 7821 |
|
|
2023
Q4 | $221K | Buy |
95,518
+84,606
| +775% | +$181K | ﹤0.01% | 8065 |
|
|
2023
Q3 | $28.5K | Sell |
10,912
-28,613
| -72% | -$90.1K | ﹤0.01% | 8256 |
|
|
2023
Q2 | $142K | Sell |
39,525
-1,380
| -3% | -$4.42K | ﹤0.01% | 7842 |
|
|
2023
Q1 | $89.2K | Sell |
40,905
-92,088
| -69% | -$293K | ﹤0.01% | 8278 |
|
|
2022
Q4 | $1.6M | Buy |
132,993
+91,008
| +217% | +$707K | ﹤0.01% | 4211 |
|
|
2022
Q3 | $272K | Sell |
41,985
-31,429
| -43% | -$254K | ﹤0.01% | 7741 |
|
|
2022
Q2 | $336K | Buy |
73,414
+43,595
| +146% | +$233K | ﹤0.01% | 7422 |
|
|
2022
Q1 | $258K | Sell |
29,819
-31,421
| -51% | -$322K | ﹤0.01% | 8623 |
|
|
2021
Q4 | $875K | Buy |
61,240
+7,930
| +15% | +$166K | ﹤0.01% | 6169 |
|
|
2021
Q3 | $1.17M | Buy |
53,310
+35,499
| +199% | +$605K | ﹤0.01% | 5600 |
|
|
2021
Q2 | $238K | Buy |
+17,811
| New | +$204K | ﹤0.01% | 8554 |
|
|
2021
Q1 | – | Sell |
-20,291
| Closed | -$86K | – | 9452 |
|
|
2020
Q4 | $86K | Sell |
20,291
-12,444
| -38% | -$40.5K | ﹤0.01% | 7238 |
|
|
2020
Q3 | $85K | Buy |
32,735
+12,193
| +59% | +$42.5K | ﹤0.01% | 6794 |
|
|
2020
Q2 | $73K | Buy |
+20,542
| New | +$68.9K | ﹤0.01% | 6787 |
|
|
2020
Q1 | – | Sell |
-38,067
| Closed | -$196K | – | 5790 |
|
|
2019
Q4 | $196K | Buy |
38,067
+14,982
| +65% | +$56.1K | ﹤0.01% | 4728 |
|
|
2019
Q3 | $74K | Sell |
23,085
-20,127
| -47% | -$67K | ﹤0.01% | 4835 |
|
|
2019
Q2 | $155K | Buy |
+43,212
| New | +$153K | ﹤0.01% | 4758 |
|
|
2014
Q2 | – | Sell |
-14,948
| Closed | -$176K | – | 2964 |
|
|
2014
Q1 | $176K | Buy |
+14,948
| New | +$252K | ﹤0.01% | 2405 |
|
Other funds holding ORMP
AF
GIA
M
BCM
BFM
Jane Street's ORMP Position: Q2 2026 in Review
Jane Street increased its Oramed Pharmaceuticals (ORMP) stake by 116% in Q2 2026, buying an estimated $242K and bringing the position to 113,349 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #7809.
Jane Street first reported a position in ORMP in Q1 2014 and has held it in 28 quarters since. The position peaked at $1.6M in Q4 2022. 83 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.
- Jane Street held 113,349 shares of Oramed Pharmaceuticals worth $545K as of Q2 2026.
- Jane Street bought 60,809 Oramed Pharmaceuticals shares in Q2 2026, an estimated $242K.
- Oramed Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7809 holding.
- Jane Street first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 28 quarters since.
- Jane Street's Oramed Pharmaceuticals position peaked at $1.6M in Q4 2022.
- 83 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.